Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Employees - 7,
CEO - Ms. Jennifer Ernst,
Sector - Healthcare,
Country - US,
Market Cap - 3.03M
Altman ZScore(max is 10): -22.64, Piotroski Score(max is 10): 2, Working Capital: $2367000, Total Assets: $2807000, Retained Earnings: $-43541000, EBIT: -5661000, Total Liabilities: $272000, Revenue: $780000
- Current Price $4.87 - Analyst Target Price $-| Ticker | TIVC |
| Index | - |
| Curent Price | 4.87 |
| Change | 49.85% |
| Market Cap | 3.03M |
| Average Volume | 644.45K |
| Income | -5.66M |
| Sales | 0.78M |
| Book Value/Share | 4.55 |
| Cash/Share | 3.22 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 9 |
| Moving Avg 20days | 48.70% |
| Moving Avg 50days | -1.72% |
| Moving Avg 200days | -7.97% |
| Shares Outstanding | 0.62M |
| Earnings Date | Mar 21 AMC |
| Inst. Ownership | 2.54% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 3.88 |
| Price/Book | 1.07 |
| Price/Cash | 1.51 |
| Price/FCF | - |
| Quick Ratio | 8.53 |
| Current Ratio | 9.70 |
| Debt/Equity | 0.00 |
| Return on Assets | -140.31% |
| Return on Equity | -184.96% |
| Return on Investment | -223.08% |
| Gross Margin | -0.13% |
| Ops Margin | -725.77% |
| Profit Margin | -725.00% |
| RSI | 58.61 |
| BETA(β) | 2.17 |
| From 52week Low | 100.41% |
| From 52week High | -84.52% |
| EPS | -29.10 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | 51.86% |
| Sales past 5 Year | 25.51% |
| EPS Y/Y | 91.72% |
| Sales Y/Y | -33.67% |
| EPS Q/Q | 89.80% |
| Sales Q/Q | -49.58% |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 0.79 |
| Perf Week | 66.78% |
| Perf Month | -2.20% |
| Perf Quarter | -17.25% |
| Perf Year | -75.93% |
| Perf YTD | -17.25% |
| Target Price | - |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer